Document is current
Any future updates will be listed below
-
Authors
Nasiri, Ali R.
Rodrigues, Marcos R.
Li, Zongyu
Leitner, Brooks P.
Perry, Rachel J. https://orcid.org/0000-0003-0748-8064
-
Funding
Funding for this research was provided by:
National Cancer Institute (CA-215315)
National Cancer Institute (CA121974-11A1)
National Institutes of Health (CTSA UL1TR000142)
National Institutes of Health (T32 GM007205)
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK045735)
Yale Cancer Center (Innovation Award)
- License Information
-
More Information
Article History
Received: 9 September 2019
Accepted: 20 November 2019
First Online: 11 December 2019
Ethics approval and consent to participate
: All animal studies were approved by the Yale University Institutional Animal Care and Use Committee.
: Not applicable.
: RJP holds investigator-initiated support from AstraZeneca for a project unrelated to cancer, examining the mechanism by which SGLT2 inhibitors may predispose to euglycemic ketoacidosis in rats, and is a co-inventor on a patent application filed by Yale University for mitochondrial uncoupling agents, including CRMP, for NAFLD. All other authors declare that they have no competing interests.
